Clinical trial
Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic…
NCT00077259 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00077259 |
|---|---|
| Title | Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer |
| Official title | A Phase II Study Of KOS-862 (Epothilone D), Administered Intravenously Weekly For 3 Weeks Every 4 Weeks, In The Second-Line Treatment Of Patients With Advanced Or Metastatic Colorectal Carcinoma (CRC) |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | epothilone D |
| Start date | Oct 1, 2003 |
| Primary completion | Sep 1, 2004 |
| First posted | Feb 11, 2004 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: